Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Manabu Takamatsu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9601-5802; OpenAlex author ID A5041000766. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2021: 1 paper · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 17

  1. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  2. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  3. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Co-author DOI 10.1007/s00428-025-04222-2↗
  4. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  5. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  6. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. First author DOI 10.1245/s10434-025-17289-7↗
  7. ASO Author Reflections: Blood Group as a Guide for Adjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1245/s10434-025-17381-y↗
  8. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  9. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
  10. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. First author DOI 10.1002/cjp2.323↗
  11. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Co-author DOI 10.1007/s00423-023-03159-x↗
  12. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  13. Diabetogenic liver metastasis from pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-022-01582-8↗
  14. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Co-author DOI 10.1245/s10434-022-11471-x↗
  15. ASO Author Reflections: Histology-Based Supervised Machine Learning Model Can Predict Recurrence Pattern of Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11540-1↗
  16. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  17. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu Takahashi · 12 shared papers, 2021–2026 · strength 2.01
  2. Naoki Sasahira · 10 shared papers, 2021–2026 · strength 1.67
  3. Yosuke Inoue · 9 shared papers, 2022–2026 · strength 1.54
  4. Hiromichi Ito · 8 shared papers, 2022–2025 · strength 1.48
  5. Atsushi Oba · 8 shared papers, 2022–2025 · strength 1.41
  6. Tsuyoshi Takeda · 8 shared papers, 2021–2026 · strength 1.26
  7. Yoshihiro Ono · 7 shared papers, 2021–2025 · strength 1.20
  8. Tsuyoshi Hamada · 6 shared papers, 2022–2026 · strength 1.15
  9. Masato Ozaka · 6 shared papers, 2021–2026 · strength 1.04
  10. Yohei Masugi · 5 shared papers, 2022–2026 · strength 0.99
  11. Takashi Sasaki · 5 shared papers, 2021–2026 · strength 0.83
  12. Tatsunori Suzuki · 5 shared papers, 2022–2026 · strength 0.79
  13. Aya Maekawa · 4 shared papers, 2024–2025 · strength 0.74
  14. Yosuke Inoue · 3 shared papers, 2024–2025 · strength 0.73
  15. Takafumi Mie · 4 shared papers, 2021–2026 · strength 0.68
  16. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63
  17. Minoru Kitago · 4 shared papers, 2022–2026 · strength 0.63
  18. Sho Uemura · 4 shared papers, 2022–2026 · strength 0.63
  19. Yousuke Nakai · 4 shared papers, 2022–2026 · strength 0.63
  20. Mitsuhiro Fujishiro · 4 shared papers, 2022–2026 · strength 0.63
  21. Yoshihiro Ono · 3 shared papers, 2022–2024 · strength 0.50
  22. Yuki Hirose · 3 shared papers, 2023–2025 · strength 0.49
  23. Takeshi Okamoto · 3 shared papers, 2021–2026 · strength 0.47
  24. Takaaki Furukawa · 3 shared papers, 2021–2026 · strength 0.47
  25. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.